DANVERS, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.
"We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "With her background and experience, Ingrid is well-positioned to maintain effective relationships with investors to help us continue growing shareholder value."
Prior to joining Abiomed, Ms. Goldberg was a Vice President at Bank of America Merrill Lynch. During her 9 year tenure at the bank, Ms. Goldberg held positions of increasing responsibility on the Capital Markets, Sales and Trading teams where she managed a ~$200mm portfolio.
"I am thrilled to be joining the Abiomed team and have already witnessed several live cases and the impact of Impella in the cath lab," said Ms. Goldberg. "The Company's compelling and innovative product portfolio, alongside the mission of providing breakthrough, minimally invasive, heart support technologies, have me eager to contribute to Abiomed becoming the new standard of care for patients requiring hemodynamic support."
Ms. Goldberg received a bachelor's degree from Princeton University where she majored in Political Science and played on the two-time National Championship and four-time Ivy League Title winning D1 Women's Lacrosse Team.
Please contact Ingrid Goldberg directly at:
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recent Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
CONTACT: For further information, please contact: Aimee Genzler Director, Corporate Communications Abiomed email@example.com 978-646-1553